Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001721325 | SCV000529433 | likely benign | not provided | 2018-06-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000617755 | SCV000736350 | likely benign | Cardiovascular phenotype | 2016-11-01 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001522311 | SCV001731827 | benign | Alagille syndrome due to a JAG1 point mutation | 2025-01-01 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001721325 | SCV005207369 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004551476 | SCV004736748 | likely benign | JAG1-related disorder | 2020-10-13 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |